NanoSanguis Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 9

Employees
  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $247K

  • Investors
  • 5

NanoSanguis General Information

Description

Developer of red blood cell substitutes designed to offer an alternative to natural blood. The company's substitutes use a biotechnology method for producing synthetic oxygen carrier that is stable for at least one year of storage and is developing blood substitutes based on full physiological, buffered fluid composed of balanced minerals compatible with the human organism, enabling clinics to meet the rapidly increasing blood deficit.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
  • Rakowiecka 36
  • Warsaw, 02-532
  • Poland

NanoSanguis Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoSanguis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 09-Nov-2020 $247K Completed Generating Revenue
2. Grant 16-Aug-2019 00000 Completed Generating Revenue
1. Early Stage VC 01-Jan-2015 Completed Startup
To view NanoSanguis’s complete valuation and funding history, request access »

NanoSanguis Patents

NanoSanguis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019367331-A1 New ammonium salts of fluorinated organic acids, method of their synthesis and application Pending 26-Oct-2018 00000000
CA-3117605-A1 New ammonium salts of fluorinated organic acids, method of their synthesis and application Pending 26-Oct-2018 00000000
EP-3870564-A2 New ammonium salts of fluorinated organic acids, method of their synthesis and application Pending 26-Oct-2018 00000000
US-20210369846-A1 New ammonium salts of fluorinated organic acids, method of their synthesis and application Pending 26-Oct-2018 A61P7/08

NanoSanguis Executive Team (4)

Name Title Board Seat Contact Info
Izabela Gałązka Chief Executive Officer
Agata Stefanek Ph.D Co-Founder & Executive
Tomasz Ciach Co-Founder & Member of Supervisory Board
You’re viewing 3 of 4 executive team members. Get the full list »

NanoSanguis Board Members (3)

Name Representing Role Since
Maciej Sadowski Startup Hub Poland Member of the Supervisory Board 000 0000
Marek Borzestowski Giza Polish Ventures President of the Supervisory Board 000 0000
You’re viewing 2 of 3 board members. Get the full list »

NanoSanguis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoSanguis Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EuroNanoMed III Other Minority 000 0000 000000 0
European Regional Development Fund (Brandenburg) Sovereign Wealth Fund 000 0000 000000 0
Giza Polish Ventures Venture Capital Minority 000 0000 000000 0
StarFinder Venture Capital Minority 000 0000 000000 0
Startup Hub Poland Accelerator/Incubator Minority 000 0000 000000 0
To view NanoSanguis’s complete investors history, request access »